Pharmacologic management of painful bladder syndrome/interstitial cystitis

A systematic review

Jordan Dimitrakov, Kurt Kroenke, William D. Steers, Charles Berde, David Zurakowski, Michael R. Freeman, Jeffrey L. Jackson

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Background: More than 180 different types of therapy have been used in the treatment and management of painful bladder syndrome/interstitial cystitis (PBS/IC), yet evidence from clinical trials remains inconclusive. This study aimed to evaluate the efficacy of pharmacologic approaches to PBS/IC, to quantify the effect size from randomized controlled trials, and to begin to inform a clinical consensus of treatment efficacy for PBS/IC. Methods: We identified randomized controlled trials for the pharmacologic treatment of patients wth PBS/IC diagnosed on the basis of National Institute of Diabetes and Digestive and Kidney Diseases or operational criteria. Study limitations include considerable patient heterogeneity as well as variability in the definition of symptoms and in outcome assessment. Results: We included a total of 1470 adult patients from 21 randomized controlled trials. Only trials for pentosan polysulfate sodium had sufficient numbers to allow a pooled analysis of effect. According to a random-effects model, the pooled estimate of the effect of pentosan polysulfate therapy suggested benefit, with a relative risk of 1.78 for patient-reported improvement in symptoms (95% confidence interval, 1.34-2.35). This result was not heterogeneous (P=.47) and was without evidence of publication bias (P=.18). Current evidence also suggests the efficacy of dimethyl sulfoxide and amitryptiline therapy. Hydroxyzine, intravesical bacille Calmette-Guérin, and resiniferatoxin therapy failed to demonstrate efficacy, but evidence was inconclusive owing to methodological limitations. Conclusions: Pentosan polysulfate may be modestly beneficial for symptoms of PBS/IC. There is insufficient evidence for other pharmacologic treatments. A consensus on standardized outcome measures is urgently needed.

Original languageEnglish
Pages (from-to)1922-1929
Number of pages8
JournalArchives of Internal Medicine
Volume167
Issue number18
DOIs
StatePublished - Oct 8 2007

Fingerprint

Interstitial Cystitis
Pentosan Sulfuric Polyester
Randomized Controlled Trials
Therapeutics
National Institute of Diabetes and Digestive and Kidney Diseases (U.S.)
Hydroxyzine
Outcome Assessment (Health Care)
Publication Bias
Dimethyl Sulfoxide
Clinical Trials
Confidence Intervals

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Dimitrakov, J., Kroenke, K., Steers, W. D., Berde, C., Zurakowski, D., Freeman, M. R., & Jackson, J. L. (2007). Pharmacologic management of painful bladder syndrome/interstitial cystitis: A systematic review. Archives of Internal Medicine, 167(18), 1922-1929. https://doi.org/10.1001/archinte.167.18.1922

Pharmacologic management of painful bladder syndrome/interstitial cystitis : A systematic review. / Dimitrakov, Jordan; Kroenke, Kurt; Steers, William D.; Berde, Charles; Zurakowski, David; Freeman, Michael R.; Jackson, Jeffrey L.

In: Archives of Internal Medicine, Vol. 167, No. 18, 08.10.2007, p. 1922-1929.

Research output: Contribution to journalArticle

Dimitrakov, J, Kroenke, K, Steers, WD, Berde, C, Zurakowski, D, Freeman, MR & Jackson, JL 2007, 'Pharmacologic management of painful bladder syndrome/interstitial cystitis: A systematic review', Archives of Internal Medicine, vol. 167, no. 18, pp. 1922-1929. https://doi.org/10.1001/archinte.167.18.1922
Dimitrakov, Jordan ; Kroenke, Kurt ; Steers, William D. ; Berde, Charles ; Zurakowski, David ; Freeman, Michael R. ; Jackson, Jeffrey L. / Pharmacologic management of painful bladder syndrome/interstitial cystitis : A systematic review. In: Archives of Internal Medicine. 2007 ; Vol. 167, No. 18. pp. 1922-1929.
@article{c2bb4640f70a4133a3321f39e6510721,
title = "Pharmacologic management of painful bladder syndrome/interstitial cystitis: A systematic review",
abstract = "Background: More than 180 different types of therapy have been used in the treatment and management of painful bladder syndrome/interstitial cystitis (PBS/IC), yet evidence from clinical trials remains inconclusive. This study aimed to evaluate the efficacy of pharmacologic approaches to PBS/IC, to quantify the effect size from randomized controlled trials, and to begin to inform a clinical consensus of treatment efficacy for PBS/IC. Methods: We identified randomized controlled trials for the pharmacologic treatment of patients wth PBS/IC diagnosed on the basis of National Institute of Diabetes and Digestive and Kidney Diseases or operational criteria. Study limitations include considerable patient heterogeneity as well as variability in the definition of symptoms and in outcome assessment. Results: We included a total of 1470 adult patients from 21 randomized controlled trials. Only trials for pentosan polysulfate sodium had sufficient numbers to allow a pooled analysis of effect. According to a random-effects model, the pooled estimate of the effect of pentosan polysulfate therapy suggested benefit, with a relative risk of 1.78 for patient-reported improvement in symptoms (95{\%} confidence interval, 1.34-2.35). This result was not heterogeneous (P=.47) and was without evidence of publication bias (P=.18). Current evidence also suggests the efficacy of dimethyl sulfoxide and amitryptiline therapy. Hydroxyzine, intravesical bacille Calmette-Gu{\'e}rin, and resiniferatoxin therapy failed to demonstrate efficacy, but evidence was inconclusive owing to methodological limitations. Conclusions: Pentosan polysulfate may be modestly beneficial for symptoms of PBS/IC. There is insufficient evidence for other pharmacologic treatments. A consensus on standardized outcome measures is urgently needed.",
author = "Jordan Dimitrakov and Kurt Kroenke and Steers, {William D.} and Charles Berde and David Zurakowski and Freeman, {Michael R.} and Jackson, {Jeffrey L.}",
year = "2007",
month = "10",
day = "8",
doi = "10.1001/archinte.167.18.1922",
language = "English",
volume = "167",
pages = "1922--1929",
journal = "JAMA Internal Medicine",
issn = "2168-6106",
publisher = "American Medical Association",
number = "18",

}

TY - JOUR

T1 - Pharmacologic management of painful bladder syndrome/interstitial cystitis

T2 - A systematic review

AU - Dimitrakov, Jordan

AU - Kroenke, Kurt

AU - Steers, William D.

AU - Berde, Charles

AU - Zurakowski, David

AU - Freeman, Michael R.

AU - Jackson, Jeffrey L.

PY - 2007/10/8

Y1 - 2007/10/8

N2 - Background: More than 180 different types of therapy have been used in the treatment and management of painful bladder syndrome/interstitial cystitis (PBS/IC), yet evidence from clinical trials remains inconclusive. This study aimed to evaluate the efficacy of pharmacologic approaches to PBS/IC, to quantify the effect size from randomized controlled trials, and to begin to inform a clinical consensus of treatment efficacy for PBS/IC. Methods: We identified randomized controlled trials for the pharmacologic treatment of patients wth PBS/IC diagnosed on the basis of National Institute of Diabetes and Digestive and Kidney Diseases or operational criteria. Study limitations include considerable patient heterogeneity as well as variability in the definition of symptoms and in outcome assessment. Results: We included a total of 1470 adult patients from 21 randomized controlled trials. Only trials for pentosan polysulfate sodium had sufficient numbers to allow a pooled analysis of effect. According to a random-effects model, the pooled estimate of the effect of pentosan polysulfate therapy suggested benefit, with a relative risk of 1.78 for patient-reported improvement in symptoms (95% confidence interval, 1.34-2.35). This result was not heterogeneous (P=.47) and was without evidence of publication bias (P=.18). Current evidence also suggests the efficacy of dimethyl sulfoxide and amitryptiline therapy. Hydroxyzine, intravesical bacille Calmette-Guérin, and resiniferatoxin therapy failed to demonstrate efficacy, but evidence was inconclusive owing to methodological limitations. Conclusions: Pentosan polysulfate may be modestly beneficial for symptoms of PBS/IC. There is insufficient evidence for other pharmacologic treatments. A consensus on standardized outcome measures is urgently needed.

AB - Background: More than 180 different types of therapy have been used in the treatment and management of painful bladder syndrome/interstitial cystitis (PBS/IC), yet evidence from clinical trials remains inconclusive. This study aimed to evaluate the efficacy of pharmacologic approaches to PBS/IC, to quantify the effect size from randomized controlled trials, and to begin to inform a clinical consensus of treatment efficacy for PBS/IC. Methods: We identified randomized controlled trials for the pharmacologic treatment of patients wth PBS/IC diagnosed on the basis of National Institute of Diabetes and Digestive and Kidney Diseases or operational criteria. Study limitations include considerable patient heterogeneity as well as variability in the definition of symptoms and in outcome assessment. Results: We included a total of 1470 adult patients from 21 randomized controlled trials. Only trials for pentosan polysulfate sodium had sufficient numbers to allow a pooled analysis of effect. According to a random-effects model, the pooled estimate of the effect of pentosan polysulfate therapy suggested benefit, with a relative risk of 1.78 for patient-reported improvement in symptoms (95% confidence interval, 1.34-2.35). This result was not heterogeneous (P=.47) and was without evidence of publication bias (P=.18). Current evidence also suggests the efficacy of dimethyl sulfoxide and amitryptiline therapy. Hydroxyzine, intravesical bacille Calmette-Guérin, and resiniferatoxin therapy failed to demonstrate efficacy, but evidence was inconclusive owing to methodological limitations. Conclusions: Pentosan polysulfate may be modestly beneficial for symptoms of PBS/IC. There is insufficient evidence for other pharmacologic treatments. A consensus on standardized outcome measures is urgently needed.

UR - http://www.scopus.com/inward/record.url?scp=35348999594&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35348999594&partnerID=8YFLogxK

U2 - 10.1001/archinte.167.18.1922

DO - 10.1001/archinte.167.18.1922

M3 - Article

VL - 167

SP - 1922

EP - 1929

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

SN - 2168-6106

IS - 18

ER -